A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer

Author(s): M. Matsuyama, R. Yoshimura

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 9 , Issue 1 , 2009

Become EABM
Become Reviewer
Call for Editor


Peroxisome proliferator activator-receptor (PPAR)-γ is a ligand-activated transcriptional factor belonging to a steroid receptor superfamily. PPAR-γ plays a role in both adipocyte differentiation and carcinogenesis. Up-date, PPAR-γ is expressed in various cancer tissues, and PPAR-γ ligand induces growth arrest of these cancer cells. In this study, we examined the expression of PPAR-γ in human urological cancer (including renal cell carcinoma, bladder tumor, prostate cancer and testicular cancer) by RT-PCR and immunohistochemistry, and we also examined the effect of PPAR-γ ligand in these cells by MTT assay, flow cytometry and hoechest staining. PPAR-γ expression was significantly more extensive and intense in malignant tissues than in normal tissues. PPAR-γ ligand induced the reduction of malignant cell viability through early apoptosis. These results demonstrated that generated PPAR-γ in urological cancer cells may play an important role in carcinogensis and become a new target therapy in the treatment of urological cancer.

Keywords: Peroxisome proliferator activator-receptor-γ, apoptosis, renal cell carcinoma, bladder tumor, prostate cancer, testicular cancer

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [76 - 83]
Pages: 8
DOI: 10.2174/187153009787582432
Price: $65

Article Metrics

PDF: 26